Shares of Mirion Technologies (MIR) are surging 5.04% in pre-market trading on Wednesday, building on the momentum from its impressive third-quarter 2025 financial results released after market close on Tuesday. The radiation measurement and nuclear medicine company outperformed analyst expectations, demonstrating robust growth and operational efficiency.

For the quarter ended September 30, Mirion reported adjusted earnings of $0.12 per share, surpassing analysts' expectations of $0.10 per share. Revenue rose 7.9% year-over-year to $223.1 million, slightly above the consensus estimate of $222.16 million. The company's GAAP net income for the quarter stood at $3.1 million, a significant improvement from a $14.0 million loss in the same period last year. Investors were particularly encouraged by Mirion's strong performance in its nuclear power end-market.

Adding to the positive sentiment, Mirion reaffirmed its full-year 2025 guidance. The company expects total revenue growth of approximately 7.0% to 9.0% for the full year, with organic revenue growth of about 4.5% to 6.0%. Mirion also maintained its adjusted EBITDA forecast of $223 million to $233 million and raised the lower end of its adjusted free cash flow guidance to $100 million - $115 million. The optimistic outlook, coupled with recent acquisitions and new orders in the pipeline, has bolstered investor confidence in Mirion's growth trajectory. Furthermore, J.P. Morgan analyst Tomohiko Sano maintained a Buy rating on Mirion Technologies, providing additional support for the stock's upward movement.